The Department of War seeks information on a modular, ruggedized autoinjector platform for delivering various CBRN medical formulations. The device must achieve 99.999% FDA-validated reliability, deliver volumes from 0.4 mL to 5.0 mL, and meet MIL-STD-810H standards for use through protective gear. Initial target compounds include Atropine, 2-PAM, Midazolam, and Naloxone. The government requires platform designs with clear dual-use pathways for commercial market viability. No budget, submission timelines, or performance location were specified.